Alpha Teknova, Inc. (TKNO)

NASDAQ: TKNO · IEX Real-Time Price · USD
-0.13 (-3.89%)
At close: Mar 17, 2023, 4:00 PM
-0.16 (-4.98%)
After-hours: Mar 17, 2023, 4:51 PM EDT

Company Description

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally.

Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics.

The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.

It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions.

The company was founded in 1996 and is headquartered in Hollister, California.

Alpha Teknova, Inc.
Alpha Teknova logo
Country United States
Founded 1996
IPO Date Jun 25, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 237
CEO Mr. Stephen Gunstream

Contact Details

2451 Bert Drive
Hollister, California 95023
United States
Phone (831) 637-1100

Stock Details

Ticker Symbol TKNO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001850902
CUSIP Number 02080L102
ISIN Number US02080L1026
Employer ID 94-3368109
SIC Code 2835

Key Executives

Name Position
Stephen Gunstream President, Chief Executive Officer and Director
Matthew C. Lowell Chief Financial Officer
Ken Gelhaus Chief Commercial Officer
Damon A. Terrill General Counsel, Chief Compliance Officer and Secretary
Jennifer Henry Senior Vice President of Marketing
Lisa Hood McCann Chief People Officer

Latest SEC Filings

Date Type Title
Mar 15, 2023 8-K Current Report
Mar 13, 2023 8-K Current Report
Jan 30, 2023 S-8 Securities to be offered to employees in employee benefit plans
Nov 14, 2022 10-Q Quarterly Report
Nov 9, 2022 8-K Current Report
Aug 11, 2022 10-Q Quarterly Report
Aug 10, 2022 8-K Current Report
Jul 12, 2022 EFFECT Notice of Effectiveness
Jul 1, 2022 S-3 Registration statement under Securities Act of 1933
Jun 3, 2022 8-K Current Report